Pyro Pharmaceuticals is a development stage drug research and development company. Pyro’s mission is clear and concise: to identify, evaluate and acquire new promising antibiotic therapeutic treatments against multi-drug resistant infectious microorganisms in humans.  

 

Pyro’s focus is on diseases in which antibiotic resistance has become a significant issue. Pyro plans to develop a new class of antibiotics for a wide variety of pathogenic microorganisms, especially those that have exhibited multiple drug resistance. Except for daptomycin (Cubicin® – 2003), which has a distinct mechanism of action, there have been no new classes of antibiotics approved in the United States in over 35 years.

 

Pyro’s portfolio of drug target patents forms the basis to develop these new antibiotics.  Since its inception in 2001, Pyro has successfully obtained one issued patent and has ten patent applications pending.